• To understand the prevalence of coexisting cardiovascular and kidney disease
• To provide guidance on detecting cardiovascular or kidney disease, and when to refer such patients for specialist care
• To describe the similarities and differences between guidelines on the management of cardiovascular and kidney disease
• To discuss the role of pharmacological treatment options in reducing both cardiovascular and renal risk

Speakers

Dr Jemima Scott NIHR Doctoral Research Fellow and Specialty Trainee in renal medicine, University of Bristol and North Bristol NHS Trust
Professor Chris Gale Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist, University of Leeds and Leeds Teaching Hospitals NHS Trust

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.

References:

1. Entresto (sacubitril/valsartan) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15041/smpc (accessed February 2025)
2. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3666/smpc (accessed February 2025)
3. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. December 2023. Available at: https://www.nice.org.uk/guidance/ng238/chapter/Recommendations (accessed February 2025)
4. NICE. Chronic kidney dissease: Scenario: Management of chronic kidney disease. September 2024. Available at: https://cks.nice.org.uk/topics/chronic-kidney-disease/management/management-of-chronic-kidney-disease/ (accessed February 2025)
5. Saeed D et al. Cureus. 2023;15:e51362
6. Song JH et al. BMC Nephrology. 2023;24:289

• Understand secondary prevention measures to implement to reduce the risk of further events in patients with established disease
• Obtain an overview of the pertinent lifestyle and medical intervention strategies available to improve outcomes
• Recognise the importance of personalised approaches to treatment to improve engagement and adherence
• Understand engaging with older patients around technology and tools they can use to maximise these resources

Speakers

Gayle Campbell Lead Heart Failure Pharmacist, Guy’s and St Thomas’ NHS Foundation Trust
Professor Pardeep Jhund Professor of Cardiology and Epidemiology and Honorary Consultant Cardiologist, University of Glasgow

Learning module instructions

This BJC learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 75%. If less time is spent learning then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

References

1. McDonagh TA et al. Eur Heart J. 2021;42:3599–3726
2. Mebazaa A et al. Lancet. 2022;400:1938–1952
3. NICE. Chronic heart failure in adults: diagnosis and management. 2018. Available at: https://www.nice.org.uk/guidance/ng106/resources/chronic-heart-failure-in-adults-diagnosis-and-management-pdf-66141541311685 (accessed January 2025)